Trials / Completed
CompletedNCT00420238
Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept (Enbrel) | 50 mg injection once weekly |
| OTHER | Placebo | placebo |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-02-01
- Completion
- 2009-05-01
- First posted
- 2007-01-11
- Last updated
- 2010-06-29
- Results posted
- 2010-06-15
Locations
21 sites across 4 countries: France, Germany, Hungary, Netherlands
Source: ClinicalTrials.gov record NCT00420238. Inclusion in this directory is not an endorsement.